Workflow
Metagenomi(MGX)
icon
Search documents
Metagenomi, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGX
GlobeNewswire News Room· 2024-10-02 17:02
Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Metagenomi, Inc. regarding a class action lawsuit related to the company's initial public offering and subsequent termination of its collaboration with Moderna [1][3]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" that had a significant partnership with Moderna, which was highlighted during its initial public offering [3]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [3]. Group 2: Allegations and Impact - The lawsuit arises from allegations that Metagenomi misled investors about its collaboration with Moderna, which was a critical aspect of its business model [3]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 within a day, indicating a significant market reaction to the news [3]. Group 3: Legal Proceedings - The class action lawsuit is on behalf of shareholders who purchased stock during the IPO period from February 9 to 13, 2024 [2]. - Shareholders are encouraged to register for the class action by November 25, 2024, to potentially become lead plaintiffs and to receive updates on the case [4].
Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX
Prnewswire· 2024-10-01 19:14
NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between Februa ...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit – MGX
GlobeNewswire News Room· 2024-09-30 17:00
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between ...
Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX
Prnewswire· 2024-09-30 09:45
NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=105586&from=4 CLASS PERIOD: This lawsuit is on beh ...
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit
Prnewswire· 2024-09-28 13:30
Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Metagenomi, Inc. stock related to its IPO conducted in February 2024, following the termination of a collaboration agreement with Moderna, which allegedly caused investor damages [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Metagenomi's IPO, where 6.25 million shares were sold at $15 each [5]. - The lawsuit claims that Metagenomi misrepresented its business relationship with Moderna, which was terminated less than three months after the IPO [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by November 25, 2024, to represent other class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4].
METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2024-09-28 01:00
Group 1 - A class action lawsuit has been filed against Metagenomi, Inc. in the United States District Court for the Northern District of California on behalf of investors who purchased Metagenomi securities during the initial public offering period from February 9, 2024, to May 1, 2024 [1] - The complaint alleges that Metagenomi made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3] - The company presented itself as a "genetic medicines company" with a significant collaboration with Moderna, claiming a Strategic Collaboration and License Agreement established on October 29, 2021, which included multiple research programs [3]
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Metagenomi Inc.
GlobeNewswire News Room· 2024-09-27 23:00
SAN DIEGO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm
GlobeNewswire News Room· 2024-09-27 22:11
Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors who purchased Metagenomi's securities during its IPO on February 9, 2024, and encourages them to contact the firm before November 25, 2024 [2]. - The lawsuit claims that Metagenomi made false and misleading statements regarding its business relationship with Moderna, which was based on a Strategic Collaboration and License Agreement from October 29, 2021 [4]. Group 2: Impact on Investors - Following the announcement of the termination of the collaboration with Moderna, investors suffered damages as the truth about Metagenomi's misleading public statements was revealed [4].
MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire News Room· 2024-09-27 20:00
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ: MGX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Metagenomi ...
METAGENOMI, INC. (NASDAQ: MGX) INVESTOR ALERT: Investors With Large Losses in Metagenomi, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
GlobeNewswire News Room· 2024-09-27 15:10
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the stock of Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024. For more information, submit a form at Metagenomi, Inc. Shareholder Class Action Lawsuit, email I ...